Citations

Clear

40 citation(s) found for "Sinclair, Rd".

Comparison of SARS-CoV-2 Delta Versus Omicron Variant and Its Impact on Immunocompromised Versus Immunocompetent Population
Shah, Sadia , SATASHIA, PARTHKUMAR , Johnson, Patrick W. , Kunze, Katie L. , Khan, A, Sinclair, Jorge, Attieh, Rose Mary , Milian, Ricardo Diaz , Edwards, Michael A. , Carter, Rickey E. , Spiecher, Leigh, Franco, Pablo Moreno , Sanghavi, Devang, Wadei, Hani M. , Carter, Rickey E , Johnson, Patrick W , Moreno Franco, Pablo , Wadei, Hani M , Kunze, Katie L , Diaz Milian, Ricardo , Isha, Shahin , Bhattacharyya, Anirban , Speicher, Leigh L. , Sanghavi, Devang, Shah, Sadia Z. , Edwards, Michael

Mayo Clinic

COVID | June 30, 2026 | Volume: 6 | Issue: 7 | Pages: 111

10.3390/covid6070111 Get It

The Omicron variant of SARS-CoV-2 is associated with milder symptoms and lower hospitalization and mortality rates than Delta variants, although the impact of Omicron on immunocompromised patients, especially solid organ transplant (SOT) recipients, is still unclear. This study compares the hospitalization rate and outcomes between immunocompromised, immunocompetent, and SOT patients during the Delta and Omicron periods. We included adult patients who tested positive for SARS-CoV-2 on PCR or nasopharyngeal antigen test between 26 June 2021 to 8 September 2022, at our institution. A total of 12,401 COVID-19 patients were included, of which 11,055 were immunocompetent, and 1346 were immunocompromised (375 SOT recipients). Throughout the Delta and Omicron outbreaks, immunocompromised patients exhibited higher comorbidities and 30-day hospitalizations, but rates of mechanical ventilation and ICU-level care were like immunocompetent patients. During the Omicron wave, immunocompromised patients had higher unadjusted relative risk estimates (RR = 2.37, 95% CI 1.96–2.87, p < 0.05) than Delta (RR = 1.58, 95% CI 1.24–2.01, p < 0.05), with higher adjusted relative risk for hospitalization in Omicron (RR = 1.50, 95% CI 1.10–2.03, p = 0.01). Analyses show increased hospitalization risk in immunocompromised during the Omicron wave compared to the Delta wave, with no significant difference in hospitalization outcomes. The relative risk of hospitalization for SOT patients was higher in both waves.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Patient-reported outcomes from the adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with HER2+ breast cancer (ATOP) trial.
Ruddy, Kathryn Jean, Ginos, Brenda, Heiling, Hillary, Rogak, Lauren , Atanasov, Stafan S., Sinclair, Sarah, Fenton, Mary Anne, Muss, Hyman, Sinclair, Natalie, Hamilton, Erika P., Dang, Chau T., Faggen, Meredith, Lo, S., Mitchell, Sandra A., Winer, Eric P., Dueck, Amylou C., Ruddy, Kathryn J. , Heiling, Hillary , Sedrak, Mina S. , Atanasov, S., Sinclair, Sarah , Mortimer, Joanne , Fenton, Mary Anne , Sinclair, Natalie, Lo, Steve, Mitchell, Sandra A , Winer, Eric P. , Dueck, Amylou C. , Freedman, Rachel A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 635-635

10.1200/jco.2026.44.16_suppl.635 Get It

635 Background: Prospective data on efficacy, quality of life, and treatment-related toxicities in older adults with breast cancer are limited. The ATOP trial (NCT03587740) evaluated T-DM1 in older adults and demonstrated favorable 5-year invasive disease-free survival. Here, we report patient-reported adverse events (AEs) and health-related quality of life (HRQOL) findings from ATOP. Methods: ATOP was a single-arm, phase II, multicenter study of adjuvant T-DM1 for those aged 60 with stage I-III HER2+ breast cancer. Protocol therapy included postoperative administration of T-DM1 (3.6 mg/kg) every 21 days for one year (17 cycles). PRO-CTCAE (assessing specific symptoms) and EQ-5D (a measure of HRQOL) surveys were administered electronically or on paper at baseline (pre-treatment), on Day 1 of each treatment cycle, and at a single 6–12-month post-treatment time point. Participants who responded to the baseline and at least one follow-up survey were included in the PRO analysis. EQ-5D changes from baseline were assessed using general linear mixed models. Summary statistics were used to assess PRO-CTCAE scores to evaluate which symptoms developed between baseline and 1 subsequent survey(s) and their severity. Results: Among the 111 patients enrolled on ATOP (median age=71, range 60-88 years), 98 responded to the baseline survey and 1 subsequent survey(s). 1435 surveys were returned that included at least one PRO-CTCAE response, and 1661 surveys were returned that included EQ-5D. The Table displays the % of participants who reported PRO-CTCAE symptoms that worsened from baseline to any severity level (scores >0) or to a severe level (scores ≥3). More than 60% of survey respondents reported new or increased dry mouth, fatigue, muscle aches, decreased appetite, nausea, pain, and/or numbness/tingling at some point during or after treatment, but these were usually not severe. EQ-5D scores did not change significantly from baseline at any time point. Conclusions: In this adjuvant trial for patients aged >60, participation rates for PRO data collection were high. Reassuringly, global HRQOL was not impacted by T-DM1, and though frequently reported, the vast majority of patient-reported symptoms were mild. Future analyses of this trial will focus on duration and predictors (clinical and biomarker-based) of severe AEs, agreement between patient-reported and clinician-reported AEs, and whether sharing PRO reports with clinicians impacted clinician-reported AE grades. Clinical trial information: NCT03587740 . Most common new or worsening symptoms reported via PRO-CTCAE in ATOP (n=95). Symptom % with score >0 n (%) with score 3+ Dry mouth 79% 26% Fatigue 71% 29% Muscle aches 69% 20% Decreased appetite 69% 12% Nausea 67% 6% Pain 66% 21% Numbness/tingling 65% 9% Blurry vision 60% 4% Mouth or throat sores 60% 5%
C66-19 Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure Ratio in Prognosis of Portopulmonary Hypertension Patients Undergoing Liver Transplant
Ghosh, S, Saunders, H, Assis, M, Corro, R, Frias, J E Sinclair De, Khanijo, A, Milian, R Diaz, Menser, T, Reddy, P, O’Sullivan, S, Patel, P, Torp, K, Burger, C D, Franco, P Moreno, Saunders, Hollie , Corro, Rosa, FRÍAS, JORGE SINCLAIR DE , Milian, Ricardo Diaz , Menser, T, O'Sullivan, S, Torp, Klaus D. , Franco, P. Moreno

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5865 Get It

Abstract Rationale Transthoracic echocardiography (TTE) is a very useful measure of cardiac function in patients with pulmonary hypertension (PH), along with right heart catheterization, which is considered to be the gold standard of measurement. It is non-invasive, quick and a good screening tool to assess the function of a failing right ventricle against elevated pulmonary pressures. Portopulmonary hypertension (POPH) is defined as PH associated with portal hypertension. The Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure (TAPSE/SPAP) ratio has been found to be an effective prognosticator in different subtypes of PH. This study focuses on the role of TAPSE/SPAP ratio in prognosis of patients with POPH undergoing liver transplantation. Methods This was a single-center retrospective study of POPH patients undergoing liver transplantation at Mayo Clinic Florida from June 2003 to December 2023. It included patients with POPH with a mean pulmonary pressure &gt;20 mm Hg undergoing liver transplantation. Patients with incomplete TTE data, coexisting renal failure on dialysis and requiring liver retransplant were excluded. This study included 27 patients. The last TTE report before liver transplantation was used for data analysis. The TAPSE/SPAP ratio was investigated as predictor of all-cause mortality following liver transplant using Cox regression and area under ROC curve. (Brackets contain 95% C.I.) Time to death after liver transplantation was considered. Patients were followed till August 1, 2024. (The correlation of this ratio-TAPSE/SPAP with some catheterization measured pulmonary pressures and indices have been included in Table 1.) Results Among 27 patients, 13 were female, 14 male. The most common causes of liver failure in these patients were non alcoholic fatty liver disease (NASH) and alcoholic liver disease. Rarely, some etiologies like sarcoidosis, autoimmune hepatitis, primary sclerosing cholangitis and hepatitis B/C were present. There were 7 deaths among total of 27 patients. The hazard ratio (HR) of TAPSE/SPAP for overall mortality by Cox regression was 0.01 (0.00-0.58), p = 0.03. The area under ROC curve was 0.76 (0.55-0.96), p = 0.01 [Also for TAPSE alone, the area under ROC curve was 0.74 (0.51-0.97), p = 0.05] Conclusion This study infers that TAPSE/SPAP ratio seems to be a good predictor of survival in POPH patients undergoing liver transplant, with a higher ratio associated with decreased all-cause mortality. It suggests that TAPSE alone might also be a good predictor with higher TAPSE associated with decreased mortality. This abstract is funded by: None
Participant Choice of Centralized or Remote Trial Engagement
Harrison, Taylor B., Sinclair, Jessica , Martin, Lisa J., Sinclair, Jessica A, McGowan, Michelle L. , Martin, Lisa J, Brinkman, William B. , Myers, Melanie F.

Mayo Clinic

JAMA Network Open | May 11, 2026 | Volume: 9 | Issue: 5 | Pages: e2612029

10.1001/jamanetworkopen.2026.12029 | PMID 42113517 Get It

This secondary analysis of a nonrandomized clinical trial identifies which participant characteristics were associated with selection of centralized or remote trial engagement.
Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study
Freedman, R. A., Heiling, H., Ruddy, K. J., Rogak, Lauren , Sedrak, M., Dueck, A., Liu, H., Fraettarelli, A., Atanasov, S., DeMeo, M. K., Lange, Paulina, Glen, A. Perilla, Sinclair, S., Dillon, D., Mortimer, J., Fenton, Mary Anne , Walsh, J., Spring, L. M., Muss, H., Sinclair, Natalie, Hamilton, E., Dang, C., Giordano, S., Faggen, Meredith, Lo, SS, Kuzma, Charles S., Lemke, Steffen , Stella, P., Mowat, Rex B., Wilkinson, Mary, Rauch, J., Tayob, Nabihah, Winer, E., Freedman, Rachel A. , Ruddy, Kathryn J. , Sedrak, Mina S. , Dueck, A., Fraettarelli, Ashton, DeMeo, Michelle K. , Perilla-Glen, Adriana, Sinclair, S., Spring, L.M., Muss, H., Dang, Catherine, Kuzma, Charles, Lemke, S.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-11-04-PS3-11-04

10.1158/1557-3265.sabcs25-ps3-11-04 Get It

Abstract Purpose: There are limited prospective data on the efficacy, tolerability, and functional impact of treatments for older and frail adults with HER2+ early breast cancer. We report the first-ever, US-based adjuvant trial dedicated to this population. Methods: We conducted a single arm, phase II, multicenter, investigator-initiated study of adjuvant ado-trastuzumab emtansine (T-DM1) in patients aged 60 and older with stage I-III HER2+ breast cancer who either declined standard adjuvant therapy or were deemed by their physician not to be candidates for standard treatment for any reason. Protocol therapy included postoperative administration of T-DM1 (3.6 mg/kg) every 21 days for one year (17 cycles). The primary endpoint was 5-year invasive disease-free survival (iDFS) with a 2-sided 90% confidence interval. Secondary endpoints presented here are toxicity and 3-year iDFS, invasive breast cancer-free survival (iBCFS), and overall survival (OS). All survival analyses were evaluated using Kaplan Meier methods and began at the time of C1D1 of T-DM1. Results: ATOP enrolled 111 evaluable patients during 2015-2020; median follow-up is 4.9 years (IQR 4.2-5.5). The median age was 71 (range 60-88); 50.4% were aged &gt;70 and 11.7% were aged &gt;80. Overall, 69.4% had stage I, 26.1% had stage II, and 4.5% had stage III disease; 70.3% had hormone receptor-positive tumors. The 5-year iDFS = 84.2% (90% CI 77.1-92.0%). The 3-year iDFS = 91.2% (90% CI 85.9%, 96.9%) and iBCFS = 94.1% (90% CI 89.7-98.8%) (see Table for event details); 3-year OS = 96.1% (90% CI 92.4-99.9%). In total, there were 3 distant recurrences and 2 breast cancer-related deaths. Overall, 82% reported grade 2+ toxicity during treatment; the most common grade 2+ events were fatigue (30.6%) and peripheral sensory neuropathy (19.8%). The most frequent grade 3 events were liver function abnormality, anemia, decreased neutrophil count, and neuropathy (&lt;5% for each); one patient (0.9%) had grade 4 thrombocytopenia. Sixty-five (58.6%) completed all 17 cycles of protocol therapy; 27 (24.3%) completed 10-16 cycles, and 19 (17.1%) completed 1-9 cycles. Reasons for early treatment discontinuation in the remaining 41.4% included toxicity (28.8%), patient withdrawal (6.3%), other (3.6%), disease progression (0.9%), death on study (0.9%, deemed unrelated to treatment), and other complicating disease (0.9%). Conclusions: The ATOP trial demonstrated a favorable 5-year iDFS and manageable toxicity among older adults with early stage HER2+ breast cancer. Although iDFS was numerically worse than historical controls (i.e., 5-year iDFS in the ‘ATEMPT’ trial by Tolaney et al. J Clin Oncol, 2024 was 97% [95% 95.2-98.7]), ATOP’s participants had higher-risk cancers, advanced age, and more competing non-breast cancer events. Future endpoints will include in-depth analyses of patient-reported outcomes, biomarkers of aging, and longitudinal functional status. Citation Format: R. A. Freedman, H. Heiling, K. J. Ruddy, L. Rogak, M. Sedrak, A. Dueck, H. Liu, A. Fraettarelli, S. Atanasov, M. DeMeo, P. Lange, A. Perilla Glen, S. Sinclair, D. Dillon, J. Mortimer, M. Fenton, J. Walsh, L. Spring, H. Muss, N. Sinclair, E. Hamilton, C. Dang, S. Giordano, M. Faggen, S. Lo, C. Kuzma, S. Lemke, P. Stella, R. Mowat, M. Wilkinson, J. Rauch, N. Tayob, E. Winer. Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-11-04.
A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)
Yee, Andrew, O'Donnell, Elizabeth, Nadeem, Omar, Nelson, Garth, Wildes, Tanya, Buck, Tondre, Tuchman, Sascha, Ghimire, Krishna, Sinclair, Sarah, Stewart, Catherine, Richardson, Paul, Usmani, Saad, Raje, Noopur, Yee, Andrew, O'Donnell, Elizabeth, Nadeem, Omar, Nelson, Garth, Wildes, Tanya, Buck, Tondre, Tuchman, Sascha, Ghimire, Krishna, Sinclair, Sarah, Stewart, Catherine, Richardson, Paul, Usmani, Saad, Raje, Noopur

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4053-4053

10.1182/blood-2025-4053 Get It

Abstract Introduction The treatment of newly diagnosed multiple myeloma (NDMM) has rapidly evolved. Quadruplet induction combining an anti-CD38 monoclonal antibody, lenalidomide, a proteasome inhibitor, and dexamethasone has become a standard of care. In this prospective randomized phase 2 trial, we evaluated the efficacy and safety of induction with a four-drug combination of daratumumab (Dara), lenalidomide (R), ixazomib (I), and dexamethasone (d) (Dara-RId) in older, transplant ineligible or deferred patients, followed by maintenance with Dara RI versus R for up to 2 years. We hypothesized that this quadruplet would offer improved tolerability with less peripheral neuropathy in this older population as well as the convenience of largely oral therapy. Herein, we present the initial results of the induction phase of the study. Methods Transplant-ineligible or deferred patients with NDMM were eligible to participate. This was a multicenter trial sponsored by the Alliance Foundation Trials, LLC, AFT-41 (NCT04009109). Each cycle of treatment was 28 days. All patients received 12 cycles of induction therapy with daratumumab 1800 mg subcutaneously on the conventional schedule, lenalidomide 15 mg orally (po) on days 1-21, ixazomib 4 mg po on days 1, 8, 15, and dexamethasone weekly. After 12 cycles, patients received maintenance based on prior randomization (1:1) to Dara-RI or R for up to 2 years. In maintenance, R was reduced to 10 mg and I was reduced to 3 mg. Randomization assignment occurred prior to starting induction. Stratification was based on presence of high-risk features defined as ISS stage III or high-risk FISH cytogenetics (del 17, t (14;16), t (14;20), t (4;14), del (1p), or gain (1q)). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and adverse events. Results We enrolled 79 patients across 7 sites from October 2020 until December 2023. Accrual was affected by the COVID19 pandemic, leading to early closure to accrual in December 2023. Median age was 74 years (range 63-86); ≥75 years of age (45.6%); female (59.5%); white (83.5%), African American (7.6%), Asian (1.3%), and Hispanic ethnicity (6.3%). Additional baseline characteristics included ISS staging I (41.8%), II (35.4%), and III (22.8%) with high-risk features in 37% by ISS stage III and/or high-risk FISH. The 12-month PFS was 92% (95% confidence interval [CI] 86.1-98.4%). The ORR (≥ partial response [PR]) during induction was 92.4% (PR 22.8%; very good partial response [VGPR] 46.8%; complete response 15.2%; stringent complete response 7.6%). Notable grade ≥3 adverse events included neutropenia (16.5%), infections (11.4%), anemia (10.1%), thrombocytopenia (8.9%), and syncope (7.6%). There was no grade ≥3 peripheral neuropathy (grade 1, 15%; grade 2, 14%). No treatment-related mortality was reported. Sixty-one patients went on to maintenance therapy and seven patients discontinued treatment for adverse events during induction (8.9%). Conclusions Dara-RId therapy in NDMM appears to be efficacious with an ORR of 92.4%; VGPR or better of 69.6% and 12-month PFS of 92%. The combination was generally tolerated well with manageable toxicity, despite 45.6% of patients being ≥75, offering the convenience of an oral proteasome inhibitor, ixazomib, that minimizes the risk of peripheral neuropathy for older, transplant-ineligible or deferred patients. Follow-up is ongoing to determine the benefit of maintenance with Dara-RI v. R alone in this population. Support: AFT, Celgene, Janssen, Takeda.
Navigating complexity: How shifting abortion regulations impacted prenatal genetic counselors practicing in restrictive states from 2020 to 2024
Holman, Darby , Smith, Nicki, Bessett, Danielle , Sinclair, Jessica , Tolusso, Leandra , Pensak, Meredith , McGowan, Michelle L. , Sinclair, Jessica A, Holman, Darby

Mayo Clinic

Journal of Genetic Counseling | September 9, 2025 | Volume: 34 | Issue: 5 | Pages: No page available

10.1002/jgc4.70103 | PMID 40922481 Get It

Abstract The 2022 Supreme Court of the United States' decision in Dobbs v. Jackson Women's Health Organization eliminated federal abortion protections, returning abortion regulation to the states. However, in many states, abortion was already heavily restricted prior to this decision. This study aimed to assess the impact of dynamic restrictive legislation passed from 2020 to 2024 on the prenatal genetic counseling process and to describe similarities and differences between state policy environments by focusing on a group of neighboring states with different legislation. Twenty‐two genetic counselors practicing in Ohio, Kentucky, and Indiana participated in focus groups ( n = 6) and one individual interview. The research team conducted reflexive thematic analysis of qualitative data. We found that participants' perspectives on the effects of legislation varied depending on state abortion policy, patient population served, and institutional resources and directives under which they worked. Most participants expressed changes to the way they document patient visits, approach counseling appointments with patients, and provide patients with resources in lieu of referrals to abortion care. Additionally, many participants expressed feeling more motivation and less burnout in the wake of restrictive legislation—a change from previous study findings. This study provides insights into the ways in which federal case law and state regulations on abortion have impacted genetic counselors' approaches to healthcare practices, documentation, and referrals to abortion care in three states that have experienced dynamic abortion regulatory environments since 2020. Findings may be useful for guiding additional support from professional societies, healthcare institutions, and training programs.
Pulmonary Arterial Pulsatility Index in Portopulmonary Hypertension
Assis, Monique Ribeiro de , Frias, J. Sinclair de, Torp, Kari, Ghosh, Souvik , Assis, M., Frias, J. Sinclair de, Franco, Pablo Moreno , Torp, K.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A4330-A4330

10.1164/ajrccm.2025.211.abstracts.a4330 Get It

Abstract Rationale Pulmonary artery pulsatility index (PAPi) is defined as pulmonary artery pulse pressure divided by right atrial pressure and has been identified as a predictor of mortality in pulmonary hypertension. Portopulmonary-hypertension (POPH), a subset associated with portal hypertension, lacks a clear prognostic association with PAPi. This study aimed to assess whether perioperative PAPi values correlate with outcomes in liver transplant patients with POPH. Methods This single-center, retrospective study included POPH patients undergoing liver transplantation at Mayo Clinic Florida from June 2003 to December 2023. 69 patients were categorized based on the lower PAPi quartile in our dataset (&gt;0.9 or ≤ 0.9), measured via catheterization within one day of transplantation, comparing baseline characteristics and outcomes. Categorical variables were analyzed using chi-square or Fisher's exact tests, while continuous variables were compared with independent t-tests or Mann-Whitney U tests. Unadjusted and adjusted odds ratios (ORs) for 1-year mortality were calculated using logistic regression for baseline comorbidities and univariate significance. Results Most patients were white (91.3%) and non-Hispanic (82.6%), with a mean BMI of 29.3 kg/m² and MELD score of 20.3. Mean hemodynamic data included heart rate of 75.8 bpm, pulmonary artery pressure of 29.9 mmHg, right atrial pressure of 15.1 mmHg, and PAPi of 1.25. Mortality rates were 7.2% at 30 days, 10.1% at 90 days, and 11.6% at 1 year. Patients with PAPi &gt;0.9 (n=50) were older (mean age 58.2 vs. 52.9) than those with PAPi ≤0.9 (n=19). The PAPi &gt;0.9 group was predominantly white (94% vs. 84.2%, p=0.04), with no significant differences in BMI, MELD scores, or ethnicity. Mortality at 30 and 90 days was higher in the PAPi &gt;0.9 group (10% and 14%, respectively) compared to the PAPi ≤0.9 group (0% for both); however, differences were not statistically significant. At 1 year, mortality was 14% in the PAPi &gt;0.9 group and 5.3% in the PAPi ≤0.9 group, with no statistical significance. Multivariate analysis indicated no association between PAPi and 1-year mortality (OR 0.12-0.24, p=0.2-0.3), and PAPi as a continuous variable showed no link with 1-year mortality. Conclusions PAPi was not significantly associated with 1-year mortality in liver transplant patients with POPH, suggesting that it should not be used alone to decide listing for transplantation. Further studies with larger cohorts are needed to confirm these findings or identify alternative hemodynamic markers or PAPi values predictive of long-term outcomes in this high-risk group.
Adolescents' and young adults' reactions to and perceived utility of carrier screening results in the context of a genomic research study
Grimes, H , McGowan, Michelle L. , Sinclair, Jessica , Prows, Cynthia A. , Lipstein, Ellen A. , Myers, Melanie F. , Grimes, Haley N , Sinclair, Jessica A, Myers, Melanie F

Mayo Clinic

Journal of Genetic Counseling | May 1, 2025 | Volume: 34 | Issue: 3 | Pages: No page available

10.1002/jgc4.70027 | PMID 40305233 Get It

AbstractAlthough guidelines have historically recommended deferring decisions about learning genomic information for conditions not actionable in childhood until adulthood, youth have increasing access to personal genomic information through research, clinical, and direct‐to‐consumer testing. However, little is known about young people's reactions to, and perceived future utility of learning genomic information actionable in adulthood. We conducted qualitative interviews with 28 youth ages 15–22 without clinical indications for genetic screening who, through enrollment in a genomic decision‐making research study, learned they were carriers of an autosomal recessive condition, or anticipated being carriers but received negative results. Semi‐structured interviews occurred virtually between 3 and 16 months after the return of results. Interpretative description guided deductive and inductive coding of transcripts. Of the 28 participants, 21 received positive carrier results, and 7 received negative results. Although some carriers felt the result was unexpected, they expressed relief overall and did not feel worried about their result. Participants with negative results also felt relief about their results. All participants correctly described what a carrier result means, but some carriers could not remember the condition associated with their result. No participant regretted learning personal genomic information, and all reported their results helped them better understand risks to future children. Carriers who perceived the condition for which they were carriers as more severe and/or those familiar with the condition were more likely to remember their result and consider future reproductive options. Carriers also felt testing at their respective age allowed increased familiarity with results and more time to gather information and decide on the personal utility of the information. Our findings suggest early access to genomic information for some youth may allow integration of carrier information over time with minimal adverse effects. More research is needed to assess long‐term outcomes among carriers.